What Researchers Did
Researchers tested the safety and efficacy of topical insulin-like growth factor 1 (IGF1) applied via gelatin hydrogels in the middle ear for patients with glucocorticoid-resistant sudden sensorineural hearing loss (SSHL).
What They Found
Among 25 patients with glucocorticoid-resistant SSHL, 48% (95% CI 28% to 69%) showed hearing improvement 12 weeks after topical IGF1 treatment. This proportion increased to 56% (95% CI 35% to 76%) at 24 weeks, and no serious adverse events were observed.
What This Means for Canadian Patients
For Canadian patients experiencing sudden sensorineural hearing loss that doesn't respond to standard steroid treatments, this novel topical therapy could offer a new option for hearing recovery. It suggests a potential way to improve hearing outcomes when conventional treatments are ineffective.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
The study's small sample size of 25 patients and comparison to historical controls limit the generalizability and strength of its findings.